NAS:ARRY (USA) Also trade in: Germany UK

Array BioPharma Inc

$ 46.62 0.04 (0.08%)
Volume: 4,275,654 Avg Vol (1m): 5,515,068
Market Cap $: 10.39 Bil Enterprise Value $: 10.10 Bil
P/E (TTM): 0.00 P/B: 33.95
Earnings Power Value -7.07
Net Current Asset Value 1.04
Tangible Book 1.37
Projected FCF -3.67
Median P/S Value 8.58
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 3.15
Cash-To-Debt ranked lower than
63.54% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ARRY: 3.15
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.49, Med: 1.76, Max: 10000
Current: 3.15
0.49
10000
Equity-to-Asset 0.53
Equity-to-Asset ranked lower than
68.28% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ARRY: 0.53
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.55, Med: 0.31, Max: 0.93
Current: 0.53
-1.55
0.93
Debt-to-Equity 0.45
Debt-to-Equity ranked lower than
62.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ARRY: 0.45
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -18.96, Med: 0.09, Max: 18.79
Current: 0.45
-18.96
18.79
Debt-to-EBITDA -1.20
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ARRY: -1.2
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -12.99, Med: -1.41, Max: 4.67
Current: -1.2
-12.99
4.67
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 21.30
DISTRESS
GREY
SAFE
Beneish M-Score 11.06
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 7.86%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -49.65
Operating Margin ranked higher than
56.19% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ARRY: -49.65
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -410.11, Med: -71.22, Max: -12.98
Current: -49.65
-410.11
-12.98
Net Margin % -52.64
Net Margin ranked higher than
55.05% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ARRY: -52.64
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -511.63, Med: -81.57, Max: 18.05
Current: -52.64
-511.63
18.05
ROE % -48.85
ROE ranked lower than
67.95% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ARRY: -48.85
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -3933.07, Med: -127.31, Max: 110.67
Current: -48.85
-3933.07
110.67
ROA % -24.66
ROA ranked higher than
53.60% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ARRY: -24.66
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -99.03, Med: -50.67, Max: 5.6
Current: -24.66
-99.03
5.6
ROC (Joel Greenblatt) % -1607.62
ROC (Joel Greenblatt) ranked lower than
63.71% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ARRY: -1607.62
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1765.06, Med: -406.16, Max: 291.72
Current: -1607.62
-1765.06
291.72
3-Year Total Revenue Growth Rate 49.60
3-Year Revenue Growth Rate ranked higher than
85.41% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ARRY: 33.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -35.9, Med: -1.7, Max: 39.8
Current: 33.7
-35.9
39.8

» ARRY's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ARRY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:ASND TSE:4587 NAS:NKTR NAS:EXEL NAS:AMRN SZSE:002007 XAMS:GLPG NAS:BLUE SZSE:002252 XBRU:ARGX SZSE:300347 NAS:MRNA NAS:NBIX SZSE:000661 NAS:ALNY BOM:532523 NAS:TECH HKSE:06160 HKSE:01530 NAS:ONCE
Traded in other countries AR2.Germany 0HI0.UK
Address 3200 Walnut Street, Boulder, CO, USA, 80301
Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

Ratios

Current vs industry vs history
PB Ratio 33.97
PB Ratio ranked lower than
83.78% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ARRY: 33.97
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 5.83, Med: 19.11, Max: 135.59
Current: 33.97
5.83
135.59
PS Ratio 41.92
PS Ratio ranked lower than
57.85% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ARRY: 41.92
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.44, Med: 7.72, Max: 42
Current: 41.92
1.44
42
EV-to-EBIT -88.77
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ARRY: -88.77
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -88.95, Med: -7.15, Max: 351.4
Current: -88.77
-88.95
351.4
EV-to-EBITDA -90.47
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ARRY: -90.47
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -90.65, Med: -7.8, Max: 173.7
Current: -90.47
-90.65
173.7
EV-to-Revenue 42.20
EV-to-Revenue ranked lower than
52.92% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ARRY: 42.2
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.1, Med: 8.1, Max: 41.6
Current: 42.2
2.1
41.6
Current Ratio 5.70
Current Ratio ranked higher than
59.12% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ARRY: 5.7
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.81, Med: 3.42, Max: 7.86
Current: 5.7
0.81
7.86
Quick Ratio 5.65
Quick Ratio ranked higher than
60.99% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ARRY: 5.65
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.81, Med: 3.33, Max: 7.55
Current: 5.65
0.81
7.55
Days Inventory 5.23
Days Inventory ranked lower than
100.00% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ARRY: 5.23
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 0, Med: 0, Max: 5.23
Current: 5.23
0
5.23
Days Sales Outstanding 48.24
Days Sales Outstanding ranked lower than
71.86% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ARRY: 48.24
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 4.61, Med: 50.33, Max: 104.04
Current: 48.24
4.61
104.04
Days Payable 54.27
Days Payable ranked higher than
55.78% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ARRY: 54.27
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 37.58, Med: 79.52, Max: 159.87
Current: 54.27
37.58
159.87

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -14.10
3-Year Share Buyback Rate ranked higher than
63.59% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ARRY: -14.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -111.3, Med: -11.8, Max: -4.2
Current: -14.1
-111.3
-4.2

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 34.02
Price-to-Tangible-Book ranked lower than
77.74% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ARRY: 34.02
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.14, Med: 5.3, Max: 123.09
Current: 34.02
1.14
123.09
Price-to-Median-PS-Value 5.43
Price-to-Median-PS-Value ranked lower than
82.45% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ARRY: 5.43
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.19, Med: 0.94, Max: 5.44
Current: 5.43
0.19
5.44
Earnings Yield (Joel Greenblatt) % -1.13
Earnings Yield (Greenblatt) ranked higher than
61.42% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ARRY: -1.13
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -95.2, Med: -9.45, Max: 5
Current: -1.13
-95.2
5

More Statistics

Revenue (TTM) (Mil) $ 239.57
EPS (TTM) $ -0.59
Beta 0.96
Volatility % 44.65
52-Week Range $ 12.56 - 47.05
Shares Outstanding (Mil) 223.1

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N